Related Experiment Videos
Tiotropium for stable chronic obstructive pulmonary disease: A meta-analysis
R G Barr1, J Bourbeau, C A Camargo
1Division of General Medicine, PH-9 East Room 105, Columbia University Medical Centre, 630 West 168th Street, New York, NY 10032, USA. rgb9@columbia.edu
Thorax
|July 18, 2006
Summary
Tiotropium effectively reduces chronic obstructive pulmonary disease (COPD) exacerbations and hospitalizations, improving patient quality of life and lung function. Further trials are needed to confirm its long-term benefits and compare it with other treatments.
Area of Science:
- Pulmonary Medicine
- Pharmacology
- Clinical Trials
Background:
- Chronic obstructive pulmonary disease (COPD) is a progressive respiratory condition characterized by airflow limitation.
- Long-acting anticholinergic bronchodilators, such as tiotropium, are a key therapeutic class for COPD management.
- Evaluating the comprehensive efficacy of tiotropium in stable COPD is crucial for optimizing patient care.
Purpose of the Study:
- To systematically review the efficacy of tiotropium in stable COPD.
- To assess tiotropium's impact on clinical events, symptom scales, pulmonary function, and adverse events.
- To compare tiotropium's effects against placebo, ipratropium bromide, and long-acting beta2 agonists (LABA).
Main Methods:
- Systematic literature search across major databases (Cochrane, MEDLINE, EMBASE, CINAHL) and hand-searched journals.
- Inclusion of randomized controlled trials (RCTs) of ≥12 weeks duration comparing tiotropium with control groups.
- Meta-analysis of pooled data to calculate odds ratios (OR) and weighted mean differences (WMD) with 95% confidence intervals (CI).
Main Results:
- Tiotropium significantly reduced the odds of COPD exacerbations (OR 0.73) and related hospitalizations (OR 0.68) compared to placebo and ipratropium.
- No significant reduction in pulmonary or all-cause mortality was observed.
- Tiotropium demonstrated greater improvements in FEV1 and FVC, and slowed FEV1 decline over one year compared to placebo and ipratropium.
Conclusions:
- Tiotropium is effective in reducing COPD exacerbations and hospitalizations, improving quality of life and symptoms.
- The drug may slow the decline in forced expiratory volume in 1 second (FEV1).
- Long-term studies are recommended to further evaluate FEV1 decline and tiotropium's comparative role against LABA.
Related Concept Videos
01:26COPD: Management Using Bronchodilators and Corticosteroids
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
01:29Chronic Obstructive Pulmonary Disease-V: Management
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
01:24Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features
Chronic bronchitis is a key phenotype of chronic obstructive pulmonary disease (COPD), characterized by airway-centered inflammation and mucus overproduction. It develops from long-term exposure to harmful particles or gases, most commonly cigarette smoke, which triggers a persistent inflammatory response.Cellular and Structural ChangesInflammation initially affects the large bronchi and later the smaller airways, with infiltration by immune cells, including neutrophils, macrophages, and...
01:20Chronic Obstructive Pulmonary Disease-I: Introduction
Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.
01:24Chronic Obstructive Pulmonary Disease
COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
01:23Chronic Obstructive Pulmonary Disease I: Introduction
Chronic obstructive pulmonary disease is a common, preventable, and treatable respiratory disorder characterized by persistent symptoms and progressive airflow limitation. This limitation results from a combination of small-airway disease (obstructive bronchiolitis) and parenchymal destruction (emphysema), both driven by chronic inflammation from exposure to harmful particles or gases.The disease includes two main pathological entities: emphysema, marked by destruction of alveolar walls and...